A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults.
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2012
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Losartan
- Indications Diabetic nephropathies; Heart failure; Hypertension
- Focus Pharmacokinetics
- 19 Sep 2011 Actual end date (June 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Mar 2011 New trial record